Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
| Current Price | ₹1,611.30 |
|---|---|
| Market Cap | ₹463 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 26.9 |
| Return on Equity | 8.06% |
| 52-Week Range | ₹1,091.10 – ₹1,774.00 |
| Beta (1Y) | 0.33 |
| Dividend Yield | 0.10% |
| Revenue | ₹73 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| EPS (Basic) | ₹8.75 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Manufacturing of Active Pharmaceutical Ingredients and Their Intermediates-100%
HALEOS LABS LIMITED is trading at ₹1,611.30, with a market capitalisation of ₹463 Cr.
HALEOS LABS LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
HALEOS LABS LIMITED has a P/E of 26.9 and a return on equity of 8.06%.
In Q1 FY27, HALEOS LABS LIMITED reported revenue of ₹73 Cr and net profit of ₹2 Cr, with basic EPS of ₹8.75 (consolidated, parsed from the company's exchange filing).